39,362 Shares in Lantheus Holdings, Inc. $LNTH Acquired by Heron Bay Capital Management

Heron Bay Capital Management bought a new stake in Lantheus Holdings, Inc. (NASDAQ:LNTH) in the second quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund bought 39,362 shares of the medical equipment provider’s stock, valued at approximately $4,367,000. Heron Bay Capital Management owned about 0.06% of Lantheus as of its most recent SEC filing.

Other large investors also recently added to or reduced their stakes in the company. Western Wealth Management LLC acquired a new position in shares of Lantheus during the 1st quarter worth $25,000. Smartleaf Asset Management LLC lifted its stake in shares of Lantheus by 63.3% in the 4th quarter. Smartleaf Asset Management LLC now owns 508 shares of the medical equipment provider’s stock valued at $34,000 after purchasing an additional 197 shares during the last quarter. Parallel Advisors LLC lifted its stake in shares of Lantheus by 122.6% in the 4th quarter. Parallel Advisors LLC now owns 541 shares of the medical equipment provider’s stock valued at $36,000 after purchasing an additional 298 shares during the last quarter. Osterweis Capital Management Inc. bought a new stake in Lantheus in the second quarter worth $36,000. Finally, Bessemer Group Inc. boosted its holdings in Lantheus by 221.2% in the first quarter. Bessemer Group Inc. now owns 514 shares of the medical equipment provider’s stock worth $39,000 after purchasing an additional 354 shares in the last quarter. 99.06% of the stock is owned by institutional investors.

Analysts Set New Price Targets

Several equities analysts have commented on the stock. Citigroup reissued an “outperform” rating on shares of Lantheus in a research report on Friday, May 8th. Weiss Ratings lowered Lantheus from a “hold (c+)” rating to a “hold (c)” rating in a report on Thursday, August 13th. Wall Street Zen downgraded Lantheus from a “strong-buy” rating to a “buy” rating in a research note on Saturday, May 9th. TD Cowen lowered Lantheus from a “buy” rating to a “hold” rating and reduced their target price for the stock from $110.00 to $102.50 in a report on Monday, August 3rd. Finally, Citizens Jmp reaffirmed a “market outperform” rating and set a $115.00 target price on shares of Lantheus in a research report on Monday, June 29th. Four research analysts have rated the stock with a Buy rating and ten have assigned a Hold rating to the company. Based on data from MarketBeat, the company currently has an average rating of “Hold” and an average price target of $108.11.

Lantheus Stock Performance

Shares of LNTH opened at $99.97 on Friday. The company has a market capitalization of $6.53 billion, a PE ratio of 24.15 and a beta of -0.03. Lantheus Holdings, Inc. has a one year low of $49.67 and a one year high of $111.86. The company has a debt-to-equity ratio of 0.43, a current ratio of 3.06 and a quick ratio of 2.89. The company’s fifty day moving average price is $104.08 and its 200 day moving average price is $90.35.

Lantheus (NASDAQ:LNTH) last released its quarterly earnings results on Thursday, August 6th. The medical equipment provider reported $1.55 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.30 by $0.25. The company had revenue of $388.18 million during the quarter, compared to analysts’ expectations of $363.23 million. Lantheus had a net margin of 17.69% and a return on equity of 28.10%. The business’s quarterly revenue was up 2.7% compared to the same quarter last year. During the same period in the prior year, the company earned $1.57 earnings per share. As a group, analysts expect that Lantheus Holdings, Inc. will post 4.48 earnings per share for the current year.

About Lantheus

Lantheus Holdings, Inc is a global life sciences company specializing in the development, manufacturing and commercialization of diagnostic imaging agents and radiopharmaceuticals. Headquartered in North Billerica, Massachusetts, Lantheus focuses on products that enhance the detection and management of cardiovascular and oncologic diseases. The company’s portfolio spans ultrasound-enhancing agents, molecular imaging tracers for positron emission tomography (PET), and emerging theranostic platforms designed to pair diagnostic and therapeutic applications.

The diagnostic imaging segment includes ultrasound contrast agents such as DEFINITY® (perflutren lipid microsphere) and Sonazoid® (perflubutane), which improve the visualization of cardiac structures and blood flow.